Mineralys Therapeutics Director RA Capital Buys 58300 Shares at $24.16/Share

martes, 31 de marzo de 2026, 4:26 pm ET1 min de lectura
MLYS--

Mineralys Therapeutics, Inc. [MLYS] has recently disclosed that Director RA CAPITAL MANAGEMENT, L.P. has made a significant investment in the company. Specifically, on March 30, 2026, the Director acquired 58,300 shares at a price of $24.16 per share. Furthermore, on March 27, 2026, the Director purchased an additional 310,700 shares at a price of $23.67 per share. These transactions demonstrate a strong commitment to the company's future prospects and may be seen as a positive indicator for investors.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios